Molecular profiles suggest two types of liver cancer should be treated as one

A comprehensive molecular analysis of two types of liver cancer, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), has identified common molecular subtypes that can be found among patients with either disease. Although HCC and ICC are considered separate diseases, the finding suggests that a unified clinical approach could benefit patients with both types of liver cancer. Read more...

New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma

Posted: Jun 22, 2017

New clinical trial studies immunotherapy and chemotherapy combination for patients with bile duct cancer for whom surgery is not an option.  Learn more...

New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma

New clinical trial studies therapy for Von Hippel-Lindau disease-associated kidney cancer

Posted: Jun 19, 2017

A new study aims to test targeted therapy in patients with Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma.  Learn more...

New clinical trial studies therapy for Von Hippel-Lindau disease-associated kidney cancer

Researchers unmask secret to long-lasting effects of botulinum neurotoxin A in motor neurons

Posted: Jun 16, 2017

A team of scientists led by the Center for Cancer Research's Allan M. Weissman, M.D., and Yien Che Tsai, Ph.D., has discovered a molecular mechanism that explains the extreme toxicity of botulinum neurotoxin A (BoNT/A), the most potent BoNT strain. The discovery, published June 5 in PNAS, also identifies a molecular target that the researchers hope will eventually lead to improved therapies to treat exposure and severely undermine the potential use of BoNTs as bioweapons.  Read more...

 

Researchers unmask secret to long-lasting effects of botulinum neurotoxin A in motor neurons

New clinical trial studies a new drug for mesothelin-positive lung cancer

Posted: Jun 15, 2017

A new phase II clinical trial is testing whether a new drug, anetumab ravtansine, can shrink tumors in mesothelin-positive lung cancer and is now recruiting patients.  Learn more...

New clinical trial studies a new drug for mesothelin-positive lung cancer

A slow “catch and release” process prolongs immune attack on cancer cells

Posted: Jun 14, 2017

Center for Cancer Research investigators have discovered that some cancer cells catch immune signaling molecules called cytokines on their surfaces then slowly release the molecules. The results suggest that the immune system may exploit this weak spot to mount a prolonged attack on the tumor. Read more...

A slow “catch and release” process prolongs immune attack on cancer cells

New clinical trial studies the immunotherapy drug pembrolizumab in patients with medullary thyroid cancer

Posted: Jun 9, 2017

A new clinical trial studies how the immunotherapy drug pembrolizumab affects patients whose medullary thyroid cancer (MTC) has returned or spread to other areas of the body. Learn more...

New clinical trial studies the immunotherapy drug pembrolizumab in patients with medullary thyroid cancer

Mark Roschewski awarded USPHS Research Physician of the Year

Posted: Jun 8, 2017

Mark Roschewski, M.D., Staff Clinician in CCR’s Lymphoid Malignancies Branch, received the Research Physician of the Year award from the Physicians Professional Advisory Committee to the Surgeon General of the U.S. Public Health Service. According to the website, this award “recognizes individual initiative, accomplishment, and accountability for actions that increase the overall effectiveness of the HHS through research.” Bill Dahut, M.D., CCR Scientific Director for Clinical Research, says, “He has the unusual ability to combine the unique sensitivity of clinical research and patient care, which has impacted patients with life-devastating lymphomas.”

Mark Roschewski awarded USPHS Research Physician of the Year

Registration open for "Cancer and Immunotherapy: From Conception to Delivery" symposium

Posted: Jun 7, 2017

The Annual Immunology Symposium, sponsored by the CCR’s Center of Excellence in Immunology will be held this fall on October 12-13th in Masur and Lipsett Auditorium in Building 10.  This year’s theme is "Cancer Immunology and Immunotherapy:  From Conception to Delivery", and the symposium will be chaired by Drs. Nicholas Restifo and Steve RosenbergLearn more...

Registration open for "Cancer and Immunotherapy: From Conception to Delivery" symposium

Using the immune system to fight, and win, the battle against cervical cancer

Posted: Jun 6, 2017

Aricca Wallace and Christian Hinrichs, M.D., catch up like old friends each time she comes to the National Institutes of Health Clinical Center for follow-up appointments. She updates him on her two boys’ wrestling competitions and state titles. He shows her pictures of the new puppy that is terrorizing his house. So far, they’ve finished each visit with Dr. Hinrichs telling her she is still cancer-free, something she never thought she would hear following her diagnosis with metastatic cervical cancer.  Read more...

Using the immune system to fight, and win, the battle against cervical cancer

Pages